AGIOS PHARMACEUTICALS, INC. (AGIO) Return on equity 2016–2025
AGIOS PHARMACEUTICALS, INC. (AGIO) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-34.6%FY2025 · since FY2016: -55.3% → -34.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -34.6% | -78.3 pp |
| FY2024 | 43.7% | +87.1 pp |
| FY2023 | -43.4% | -22.4 pp |
| FY2022 | -21.1% | -145.3 pp |
| FY2021 | 124.2% | +206.2 pp |
| FY2020 | -81.9% | -17.7 pp |
| FY2019 | -64.2% | -13.9 pp |
| FY2018 | -50.3% | +33.5 pp |
| FY2017 | -83.8% | -28.5 pp |
| FY2016 | -55.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More AGIO financial trends
AGIO RevenueAGIO Net incomeAGIO Net marginAGIO Gross profitAGIO Gross marginAGIO Operating incomeAGIO Operating marginAGIO Operating cash flowAGIO Free cash flowAGIO Capital expendituresAGIO Stock buybacksAGIO Dividends paidAGIO Total assetsAGIO Total liabilitiesAGIO Shareholders’ equityAGIO overview →